title: A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells.
abstract: BACKGROUND
  The development of effective cancer vaccines still remains a challenge. Despite the crucial role of plasmacytoid dendritic cells (pDCs) in anti-tumor responses, their therapeutic potential has not yet been worked out. We explored the relevance of HLA-A*0201 matched allogeneic pDCs as vectors for immunotherapy.
  
  
  RESULTS
  Stimulation of PBMC from HLA-A*0201(+) donors by HLA-A*0201 matched allogeneic pDCs pulsed with tumor-derived peptides triggered high levels of antigen-specific and functional cytotoxic T cell responses (up to 98% tetramer(+) CD8 T cells). The pDC vaccine demonstrated strong anti-tumor therapeutic in vivo efficacy as shown by the inhibition of tumor growth in a humanized mouse model. It also elicited highly functional tumor-specific T cells ex-vivo from PBMC and TIL of stage I-IV melanoma patients. Responses against MelA, GP100, tyrosinase and MAGE-3 antigens reached tetramer levels up to 62%, 24%, 85% and 4.3% respectively. pDC vaccine-primed T cells specifically killed patients' own autologous melanoma tumor cells. This semi-allogeneic pDC vaccine was more effective than conventional myeloid DC-based vaccines. Furthermore, the pDC vaccine design endows it with a strong potential for clinical application in cancer treatment.
  
  
  CONCLUSIONS
  These findings highlight HLA-A*0201 matched allogeneic pDCs as potent inducers of tumor immunity and provide a promising immunotherapeutic strategy to fight cancer.
authors.affiliation: Etablissement Français du Sang Rhone-Alpes, R&D Laboratory, La Tronche, France. carolineaspord@yahoo.com
authors.forename: Caroline
authors.initials: C
authors.lastname: Aspord
authors.forename: Julie
authors.initials: J
authors.lastname: Charles
authors.forename: Marie-Therese
authors.initials: MT
authors.lastname: Leccia
authors.forename: David
authors.initials: D
authors.lastname: Laurin
authors.forename: Marie-Jeanne
authors.initials: MJ
authors.lastname: Richard
authors.forename: Laurence
authors.initials: L
authors.lastname: Chaperot
authors.forename: Joel
authors.initials: J
authors.lastname: Plumas
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology*; D018450:Disease Progression; D000939:Epitopes / Q000276:immunology; D015234:HLA-A Antigens / Q000276:immunology*; D015789:HLA-A2 Antigen; D006262:Health; D006650:Histocompatibility Testing; D006801:Humans; D008545:Melanoma / Q000276:immunology* / Q000473:pathology; D051379:Mice; D009367:Neoplasm Staging; D010455:Peptides / Q000276:immunology; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology; D014019:Tissue Donors; D014611:Vaccination
chemical_list: D019496:Cancer Vaccines; D000939:Epitopes; D015234:HLA-A Antigens; C435939:HLA-A*02:01 antigen; D015789:HLA-A2 Antigen; D010455:Peptides
references.citation: Leukemia. 2005 Sep;19(9):1621-7
references.pmid: 15990861
references.citation: Nat Immunol. 2008 May;9(5):551-7
references.pmid: 18376401
references.citation: J Immunol. 2006 Jan 1;176(1):248-55
references.pmid: 16365416
references.citation: Clin Cancer Res. 2008 Jul 15;14(14):4532-42
references.pmid: 18628468
references.citation: Nat Rev Immunol. 2006 May;6(5):383-93
references.pmid: 16622476
references.citation: Int J Med Microbiol. 2008 Jan;298(1-2):11-20
references.pmid: 17719274
references.citation: Nat Immunol. 2000 Oct;1(4):305-10
references.pmid: 11017101
references.citation: J Exp Med. 2000 Dec 18;192(12):1785-96
references.pmid: 11120775
references.citation: Am J Transplant. 2005 Aug;5(8):1808-19
references.pmid: 15996227
references.citation: J Pathol. 2003 Jun;200(2):255-68
references.pmid: 12754747
references.citation: Int J Cancer. 2004 Jul 10;110(5):730-40
references.pmid: 15146563
references.citation: J Immunother. 2005 Mar-Apr;28(2):158-68
references.pmid: 15725960
references.citation: J Clin Invest. 2005 Jun;115(6):1616-26
references.pmid: 15931392
references.citation: Nat Med. 2001 Dec;7(12):1339-46
references.pmid: 11726975
references.citation: Immunology. 2007 Jun;121(2):149-57
references.pmid: 17371541
references.citation: J Clin Oncol. 2005 Apr 1;23(10):2346-57
references.pmid: 15800326
references.citation: J Clin Invest. 2007 May;117(5):1184-94
references.pmid: 17476348
references.citation: Immunity. 2008 Sep 19;29(3):372-83
references.pmid: 18799145
references.citation: J Clin Invest. 2008 Mar;118(3):1165-75
references.pmid: 18259609
references.citation: J Immunol. 2007 Mar 1;178(5):2763-9
references.pmid: 17312119
references.citation: J Clin Invest. 2004 Mar;113(5):774-83
references.pmid: 14991076
references.citation: J Immunol. 2004 Sep 1;173(5):3051-61
references.pmid: 15322165
references.citation: Nat Immunol. 2004 Dec;5(12):1219-26
references.pmid: 15549123
references.citation: Annu Rev Immunol. 2005;23:275-306
references.pmid: 15771572
references.citation: Semin Immunol. 1998 Oct;10(5):351-3
references.pmid: 9799709
references.citation: Blood. 2009 Aug 27;114(9):1794-802
references.pmid: 19553637
references.citation: Eur J Immunol. 1987 Nov;17(11):1579-83
references.pmid: 2445585
references.citation: Nat Immunol. 2008 Nov;9(11):1244-52
references.pmid: 18849989
references.citation: BJU Int. 2006 Nov;98(5):989-95
references.pmid: 16879440
references.citation: Clin Dev Immunol. 2008;2008:106321
references.pmid: 19190769
references.citation: Cancer Immunol Immunother. 2005 Jul;54(7):663-70
references.pmid: 15918076
references.citation: Immunity. 2008 Sep 19;29(3):352-61
references.pmid: 18799143
references.citation: Nat Rev Immunol. 2005 Apr;5(4):296-306
references.pmid: 15803149
references.citation: Science. 1999 Jun 11;284(5421):1835-7
references.pmid: 10364556
references.citation: N Engl J Med. 2008 Jun 19;358(25):2704-15
references.pmid: 18565863
references.citation: Cancer Res. 2003 Oct 1;63(19):6478-87
references.pmid: 14559840
references.citation: Clin Cancer Res. 2004 Nov 15;10(22):7466-74
references.pmid: 15569976
references.citation: J Exp Med. 1999 Dec 6;190(11):1669-78
references.pmid: 10587357
references.citation: Nat Immunol. 2008 Nov;9(11):1208-10
references.pmid: 18936779
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6092-7
references.pmid: 15079077
references.citation: Blood. 2003 May 1;101(9):3520-6
references.pmid: 12511409
references.citation: Blood. 2002 Jul 15;100(2):701-3
references.pmid: 12091369
references.citation: J Exp Med. 2007 Aug 6;204(8):1923-33
references.pmid: 17646404
references.citation: Cancer Immunol Immunother. 2007 Dec;56(12):2003-16
references.pmid: 17333181
references.citation: Expert Opin Drug Discov. 2007 Jul;2(7):949-60
references.pmid: 23484815
references.citation: PLoS One. 2009 Sep 22;4(9):e7111
references.pmid: 19771163
references.citation: Blood. 2004 Mar 15;103(6):2162-9
references.pmid: 14630815
references.citation: Nat Med. 2001 Jun;7(6):649-52
references.pmid: 11385492
references.citation: Transpl Immunol. 1993;1(2):126-31
references.pmid: 8081770
references.citation: Clin Cancer Res. 2007 May 15;13(10):2961-9
references.pmid: 17504997
references.citation: Cancer Immunol Immunother. 2006 Dec;55(12):1480-90
references.pmid: 16468034
references.citation: J Immunother. 2000 Mar-Apr;23(2):246-54
references.pmid: 10746551
references.citation: Eur J Immunol. 2003 Apr;33(4):1052-62
references.pmid: 12672071
references.citation: Blood. 2004 Sep 15;104(6):1808-15
references.pmid: 15166034